Affiliation: | 1.Otsuka Pharmaceutical Development & Commercialization, Inc, Princeton, NJ, 08540, USA ;2.Health Analytics, LLC 9200 Rumsey Rd Suite 215, Columbia, MD, 21045, USA ; |
Abstract: | Little is known about the association between patient activation, health, service utilization, and cost among mental health (MH) patients. Patients aged 18 to 64 with schizophrenia (Sz, n =?43), bipolar disorder (BD, n =?59), or major depressive disorder (MDD, n =?34) completed the Patient Activation Measure for Mental Health (PAM-MH), the Colorado Symptom Index, demographic, socioeconomic, treatment, and social support questionnaire items. Average PAM-MH score indicated BD patients the most activated (66.6?±?17.5), Sz (57.4?±?10.4) less activated, and MDD the least activated (55.4?±?14.6). The MDD cohort had the highest ($27,616?±?26,229) and the BD had the lowest total annual healthcare cost ($18,312?±?25,091). PAM-MH score was inversely correlated with healthcare costs and regression analysis showed a PAM-MH score × gender interaction. The strongest negative relationship between PAM and cost was for males. These analyses support the inverse association between PAM-MH and healthcare service utilization and cost. |